The Evolving Management of Bone Disease:
Changes on the Horizon

Course Chairperson
Ethel S. Siris, MD
Madeline C. Stabile Professor of Clinical Medicine
Director, Toni Stabile Osteoporosis Center
Metabolic Bone Diseases Program
Department of Medicine
College of Physicians and Surgeons of Columbia University
Columbia-Presbyterian Medical Center
New York, New York, United States

Course Faculty
Jacques P. Brown, MD, FRCP
Clinical Professor
Department of Medicine at Laval University
Head of the Division of Rheumatology
Le Centre Hospitalier Universitaire de Québec
Sainte-Foy, Québec, Canada

John A. Kanis, BSc, MB ChB, MD, FRCP, FRCPath
Professor in Human Metabolism
Director, WHO Collaborating Centre for Metabolic Bone Disease
University of Sheffield Medical School
Sheffield, United Kingdom

R. Graham Russell, MD, PhD
Professor
Botnar Research Centre
Nuffield Department of Orthopaedic Surgery
Norman Collission Chair of Musculoskeletal Sciences
University of Oxford, Nuffield Orthopaedic Centre
Oxford, United Kingdom

Faculty Disclosure Statements
In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, the faculty for this activity have been asked to complete a Conflict of Interest Disclosure form. Disclosure is required to be provided to attendees or participants.

The following faculty members disclosed program- or content-related financial affiliations:

Jacques P. Brown, MD, FRCP
Dr Brown has received research support from, and has been a speaker for, Alliance Pharmaceutical Corp.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; NPS Pharmaceuticals; Pfizer Inc.; Servier; and Wyeth.

He knowingly includes in his education session the discussion of an unlabeled or investigative use of commercial products.

John A. Kanis, BSc, MB ChB, MD, FRCP, FRCPath
Prof Kanis does not have any significant financial arrangement or affiliation with commercial companies whose products may be mentioned in this program.

Graham Russell, MD, PhD
Prof Russell has received research support from, and been a consultant for, Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Procter & Gamble; and Roche Pharmaceuticals.

He knowingly includes in his education session the discussion of an unlabeled or investigative use of commercial products.

Ethel S. Siris, MD
Dr Siris has been a consultant for The Alliance for Better Bone Health; Eli Lilly and Company; Merck & Co.; and Novartis Pharmaceuticals Corporation. She has also been a speaker for Eli Lilly and Company; Merck & Co., Inc.; and Procter & Gamble.

She knowingly includes in her education session the discussion of an unlabeled or investigative use of commercial products.

Printer settings may vary. Please use landscape layout option.